Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Eli Lilly and Co News & Analysis
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
markets
June 2025 US stock market outlook: Has the storm passed?
Be wary of the recent complacency; there’s turbulent water ahead before the skies clear.
markets
US stock market outlook: Where we see opportunities in Q2
A bear market in AI stocks leads to more attractive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,136.60 | 15.10 | 0.17% |
CAC 40 | 7,966.95 | 71.01 | 0.90% |
DAX 40 | 24,113.62 | 232.90 | 0.98% |
Dow JONES (US) | 46,375.36 | 22.53 | -0.05% |
FTSE 100 | 9,446.43 | 96.00 | 1.03% |
HKSE | 26,855.56 | 232.68 | 0.87% |
NASDAQ | 22,694.54 | 34.53 | 0.15% |
Nikkei 225 | 44,550.85 | 381.78 | -0.85% |
NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
S&P 500 | 6,692.03 | 3.57 | 0.05% |
S&P/ASX 200 | 8,845.70 | 12.30 | 0.14% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |